PAK4 and cancer: As mutations of PAK4 and RYR1 tend to co-occur in HGSOC, and the two genes might interact, we hypothesize that caffeine, a cancer drug that targets RYR1 [80] (S7 Fig), may represent a useful intervention strategy to treat HGSOC patients with PAK4 mutations.